Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03691350 · ClinicalTrials.gov registry record · Early Phase 1
Bronchoscopy in Determining the Effect of E-Cigarette Smoking on Biomarkers in the Lungs
A Early Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 66
- Enrollment target
NCT03691350: Completed Early Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT03691350 is a Early Phase 1 study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 66 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (25% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03691350, a Early Phase 1 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This trial studies biomarkers obtained by bronchoscopy (bronchoalveolar lavage and lung brushings) to determine the effect of smoking e-cigarettes on the lungs. Studying samples of lung cells from participants who smoke e-cigarettes may help doctors learn more about changes that occur in deoxyribonucleic acid and identify biomarkers related to cancer.
Primary Outcome
Obtained via bronchoscopy with saline bronchoalveolar lavage (BAL) and bronchial brushings. Descriptive statistics and clustering (e.g., principal components analysis \[PCA\]), will be performed for all biomarker data measured at the different visits. Baseline data (1st bronchoscopy) will then be compared between the four groups (3 conditions and control) using a one-way analysis of variance (ANOVA). The non-parametric Kruskal-Wallis test (continuous or ordinal variables) or the chi-square test
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Bronchoscopy with Bronchoalveolar Lavage
- DRUG Cigarette
- OTHER Electronic Cigarette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2018-09-17 |
| Est. Completion | 2024-03-10 |
| Phase | Early Phase 1 |
What the finished NCT03691350 record still lists
NCT03691350 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (25% higher).
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03691350 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03691350 about?
NCT03691350 is a clinical study titled "Bronchoscopy in Determining the Effect of E-Cigarette Smoking on Biomarkers in the Lungs". This trial studies biomarkers obtained by bronchoscopy (bronchoalveolar lavage and lung brushings) to determine the effect of smoking e-cigarettes on the lungs. Studying samples of lung cells from participants who smoke e-cigarettes may help doctors learn more about changes that occur in deoxyribonu...
What is the current status of trial NCT03691350?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 66 participants. The study started on 2018-09-17. Estimated completion is 2024-03-10.
What interventions are being tested in trial NCT03691350?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Bronchoscopy with Bronchoalveolar Lavage (PROCEDURE), Cigarette (DRUG), Electronic Cigarette (OTHER).
Who is sponsoring clinical trial NCT03691350?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03691350's enrollment target sits among peer trials
66 363rd of 2000 higher than 1,630 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI